Go Pro
→ Central banks bought 710 tonnes - this fund pays monthly (From Investors Alley) (Ad)tc pixel Free STAB Stock Alerts

Statera Biopharma (STAB) Competitors

Statera Biopharma logo
$0.0002 0.00 (0.00%)
As of 08/13/2026
Compare

STAB vs. NAVB, GNCA, PXMD, ARDS, and GNCAQ

Should you buy Statera Biopharma stock or one of its competitors? Statera Biopharma's main competitors and comparable companies include Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), Aridis Pharmaceuticals (ARDS), and Genocea Biosciences (GNCAQ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Statera Biopharma compare to Navidea Biopharmaceuticals?

Statera Biopharma (NASDAQ:STAB) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Statera Biopharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Navidea Biopharmaceuticals Neutral

Statera Biopharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Navidea Biopharmaceuticals beats Statera Biopharma on 5 of the 5 factors compared between the two stocks.

How does Statera Biopharma compare to Genocea Biosciences?

Statera Biopharma (NASDAQ:STAB) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Statera Biopharma has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

0.6% of Genocea Biosciences shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Statera Biopharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Genocea Biosciences Neutral

Statera Biopharma has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Summary

Genocea Biosciences beats Statera Biopharma on 4 of the 7 factors compared between the two stocks.

How does Statera Biopharma compare to PaxMedica?

Statera Biopharma (NASDAQ:STAB) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

4.9% of PaxMedica shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Statera Biopharma's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
PaxMedica Neutral

Statera Biopharma has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Summary

Statera Biopharma beats PaxMedica on 4 of the 6 factors compared between the two stocks.

How does Statera Biopharma compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
Statera BiopharmaN/AN/AN/AN/AN/A

Aridis Pharmaceuticals has a beta of 49.62, indicating that its share price is 4,862% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Statera Biopharma N/A N/A N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Statera Biopharma Neutral

Summary

Aridis Pharmaceuticals beats Statera Biopharma on 3 of the 3 factors compared between the two stocks.

How does Statera Biopharma compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Statera Biopharma Neutral

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Statera Biopharma N/A N/A N/A

Genocea Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Statera BiopharmaN/AN/AN/AN/AN/A

Summary

Genocea Biosciences beats Statera Biopharma on 2 of the 2 factors compared between the two stocks.

Get Statera Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STAB vs. The Competition

Export
MetricStatera BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3K$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio0.00775.15269.0625.28
Price / SalesN/A743.50592.5787.62
Price / CashN/A66.4570.4850.90
Price / BookN/A11.6012.916.24
Net IncomeN/A$2.77B$3.45B$347.60M
7 Day PerformanceN/A0.17%1.12%1.07%
1 Month PerformanceN/A0.35%1.79%1.03%
1 Year PerformanceN/A161.52%67.69%20.77%

Statera Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STAB
Statera Biopharma
N/A$0.00
flat		N/A+100.0%$3KN/AN/A20
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A2
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$5KN/A0.0030

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:STAB) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why I'm sending this one to my own family
Behind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...
Behind the Markets | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel